Revenue from operations declined to Rs 2,777 crore in the June quarter as compared with Rs 2,965 crore in the year-ago period.
“We delivered a strong double digit growth in our base business during the quarter excluding the impact of COVID-related products,” Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said in a regulatory filing.
Europe and ROW markets performed well despite the challenging macro-economic environment, and the India base business also recorded strong growth, he added.
“Our goal is to continue growing our base business through new product launches in our key focus areas of respiratory, dermatology and oncology,” Saldanha noted.
Shares of the Mumbai-based drug firm settled 1.02 per cent up at Rs 375.7 apiece on BSE.